Cancer prevention with a single jab - 20/05/2026

Therapeutic vaccine against HPV-induced tumours

Persistent infections with human papillomaviruses (HPV) are the primary cause of cervical cancer. Researchers from Heidelberg have developed a promising therapeutic vaccine consisting of immunogenic virus peptides linked to silica nanoparticles, which is currently being investigated in preclinical studies. The vaccine activates specific cytotoxic T cells and is usable regardless of HLA type.

Research jointly led by scientists at the Heidelberg site of the German Center for Lung Research and investigators in Boston at Massachusetts General Hospital and Harvard Medical School identifies a new immunotherapy-based approach for lung fibrosis: reactivating natural killer cell (NK cells) to eliminate senescent fibroblasts, reverse scarring and restore the lung’s ability to heal.

Medical Center – University of Freiburg demonstrates a fundamental therapeutic approach for hereditary immune system defects in a mouse model. The safety profile of genome editing varies significantly depending on the method and cell type.

The Collaborative Research Centre (CRC) 1550 “Molecular Circuits of Heart Disease” at Heidelberg University is entering its second funding period. The German Research Foundation (DFG) has approved approximately EUR 17.4 million in funding for the next four years. The spokesperson is Johannes Backs, Professor of Experimental Cardiology at the Heidelberg Faculty of Medicine.

The Medical Center – University of Freiburg has been certified for the first time as a “Center of Excellence” by the European Neuroendocrine Tumor Society (ENETS). The professional association recognizes specialized centers that treat rare tumor diseases in accordance with established quality standards. Neuroendocrine tumors are rare cancers that can arise from hormone-producing cells.